Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence

Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study

(2018) Nicola P. Klein et al.   VACCINE

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study

(2018) Clare L. Cutland et al.   VACCINE

Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine

(2018) Markus Knuf et al.   VACCINE

MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial

(2018) Luis Rivera et al.   VACCINE

Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines

(2018) Emile F.F. Jonker et al.   VACCINE

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study

(2018) Ghassan Dbaibo et al.   VACCINE

Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study

(2018) Luis Rivera et al.   VACCINE

Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents

(2018) Lidia C. Serra et al.   JOURNAL OF ADOLESCENT HEALTH

Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies

(2018) Robert Booy et al.   Human Vaccines & Immunotherapeutics

Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants

(2017) Jose Manuel Merino Arribas et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination

(2017) Mariëtte B. van Ravenhorst et al.   VACCINE

Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial

(2017) Mariëtte B. van Ravenhorst et al.   VACCINE

Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults

(2017) Marieke van der Heiden et al.   VACCINE

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents

(2017) Beatriz P. Quiambao et al.   Human Vaccines & Immunotherapeutics

Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults

(2017) Marieke van der Heiden et al.   Frontiers in Immunology

Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements

(2016) Federico Martinón-Torres   JOURNAL OF ADOLESCENT HEALTH

Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children

(2016) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers

(2016) Gianni Bona et al.   VACCINE

Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein

(2016) Ali Saber Abdelhameed et al.   Scientific Reports

A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate

(2016) Ali Saber Abdelhameed et al.   Scientific Reports

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents

(2016) Beatriz P. Quiambao et al.   Human Vaccines & Immunotherapeutics

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial

(2015) Charissa Fay Corazon Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Neisseria meningitidis: pathogenesis and immunity

(2015) Mariagrazia Pizza et al.   CURRENT OPINION IN MICROBIOLOGY

Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age

(2015) David A. Ishola et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults

(2015) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines

(2015) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae–N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy

(2015) Michael Leonardi et al.   VACCINE

Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™

(2015) Michael Leonardi et al.   VACCINE

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

(2013) Charissa Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Meningococcal Polysaccharide AO-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

(2013) Socorro Lupisan et al.   Clinical and Vaccine Immunology

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

(2013) Ghassan Dbaibo et al.   DRUGS & AGING

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

(2013) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Protein carriers of conjugate vaccines: Characteristics, development and clinical trials

(2013) Michael E Pichichero   Human Vaccines & Immunotherapeutics

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age

(2013) S. A. Halperin et al.   Journal of the Pediatric Infectious Diseases Society

An asymmetric and slightly dimerized structure for the tetanus toxoid protein used in glycoconjugate vaccines

(2012) Ali Saber Abdelhameed et al.   CARBOHYDRATE POLYMERS

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)

(2012) Lars Østergaard et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers

(2012) Guillermo M. Ruiz-Palacios et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal disease: Clinical presentation and sequelae

(2012) David Pace et al.   VACCINE

History of meningococcal vaccines and their serological correlates of protection

(2012) Caroline Vipond et al.   VACCINE

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults

(2012) Mari Rose Aplasca-De Los Reyes et al.   Human Vaccines & Immunotherapeutics

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   Human Vaccines & Immunotherapeutics

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers

(2011) Jodie McVernon et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

(2011) Timo Vesikari et al.   VACCINE

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial

(2011) Lars Østergaard et al.   VACCINE

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

(2008) J. Southern et al.   Clinical and Vaccine Immunology

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE